Table 3.
Methylation modification and its interaction with various type of lncRNAs in BC studies: LncRNA → histone methylation and Histone methylation → lncRNA
| Long ncRNA | Expression in BC | Signaling pathway involved | Mechanism of action | References |
|---|---|---|---|---|
| LINC00511 | ↑ | LINC00511/EZH2/PRC2/CDKN1B | Suppression of CDKN1B expression in ER− BC | [247] |
| ROR | ↑ | ROR/MLL1/TIMP3 | Support of BC progression | [248] |
| UCA1 | ↑ | UCA1/EZH2/p21 | Supporting of tamoxifen resistance of BC cells | [249] |
| PHACTR2-AS1 | ↓ | EZH2/PHACTR2-AS1/Ribosome DNA | Suppression of the BC cell growth and metastasis | [250] |
| HOTAIRM1 | ↑ | HOTAIRM1/EZH2/PRC2/HOXA1 | Promotion of tamoxifen resistance in ER+ BC cells | [251] |
| LINC02273 | ↑ | LINC02273/AGR2 | Promotion of BC metastasis | [252] |
| DANCR | ↑ | DANCR/EZH2/SOCS3 | Promotion of EMT, cancer stemness, and inflammation in BC | [253] |
| EPB41L4A-AS2 | ↓ | ZNF217/EZH2/EPB41L4A-AS2 | Promotion of BC progression | [254] |
| DLEU1 | ↑ | DLEU1/SRP4 | Promotion of BC progression | [255] |
Abbreviations: ↑, increased, upregulated; ↓, reduced, downregulated; BBM, breast to brain metastases; BCSCs, breast cancer stem cells